Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 2, 2009, Pages 130-141

  Bulitta, Jürgen B ^a   Duffull, Stephen B ^b   Landersdorfer, Cornelia B ^a   Kinzig, Martina ^a   Holzgrabe, Ulrike ^c   Stephan, Ulrich ^a,d   Drusano, George L ^e   Sörgel, Fritz ^a,d  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Allometric scaling by lean body mass; Cystic fibrosis healthy volunteers; Monte Carlo simulation; PK PD MIC breakpoints; Population pharmacokinetics pharmacodynamics of carumonam

Indexed keywords

CARUMONAM; CREATININE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; LEAN BODY WEIGHT; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PLASMA; SPECTROPHOTOMETRY, ULTRAVIOLET; YOUNG ADULT;

EID: 69949086657     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.06.018     Document Type: Article

References (57)

1. Al-Aloul M., Jackson M., Bell G., Ledson M., and Walshaw M. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J. Cyst. Fibros. 6 (2007) 41-47
2. Anderson B.J., and Holford N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 303-332
3. Beal S.L., Boeckmann A.J., Sheiner L.B., and NONMEM Project Group. NONMEM users guides (1999), University of California at San Francisco, San Francisco
4. Berube D., Vallee F., Panneton A.C., Bergeron M.G., and LeBel M. Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Antimicrob. Agents Chemother. 32 (1988) 354-357
5. Bulitta J.B., Duffull S.B., Landersdorfer C.B., Drusano G.L., Kinzig-Schippers M., Holzgrabe U., Stephan U., and Sörgel F. Pharmacodynamic comparison of cystic fibrosis patients and healthy volunteers by population pharmacokinetics (PK) and Monte Carlo simulation. Poster W4056. AAPS Annual Meeting, San Antonio, TX, USA (2006)
6. Bulitta J.B., Duffull S.B., Kinzig-Schippers M., Holzgrabe U., Stephan U., Drusano G.L., and Sorgel F. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51 (2007) 2497-2507
7. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin. Pharmacokinet. 39 (2000) 215-231
8. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998) 1-12
10. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopepq8hes, and linezolid. Infect. Dis. Clin. North Am. 17 (2003) 479-501
11. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat. Rev. Microbiol. 2 (2004) 289-300
12. Efron B., and Tibshirani R.J. Bootstrap methods for standard errors, confidence intervals and other measures of statistical accuracy. Stat. Sci. 1 (1986) 54-77
13. Gibson R.L., Burns J.L., and Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168 (2003) 918-951
14. Gottschalk B., Sorgel F., Wiesemann H.G., Stephan U., Rey M., Bowing H.B., Stehr C., Dominick H.C., Kiosz D., and Geldmacher-von Mallinckrodt M. Antibiotic pharmacokinetics in patients with mucoviscidosis. Monatsschr. Kinderheilkd. 136 (1988) 475-478
15. Green B., and Duffull S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br. J. Clin. Pharmacol. 58 (2004) 119-133
16. Hedman A., Adan-Abdi Y., Alvan G., Strandvik B., and Arvidsson A. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin. Pharmacokinet. 15 (1988) 57-65
17. Hedman A., Alvan G., Strandvik B., and Arvidsson A. Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis. Clin. Pharmacokinet. 18 (1990) 168-175
18. Holford N.H. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30 (1996) 329-332
19. Igari J., Oguri T., Hiramatsu N., Akiyama K., and Koyama T. Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates-II. Gram-negative bacteria. Jpn. J. Antibiot. 56 (2003) 458-496
20. Ikemoto H., Watanabe K., Mori T., Igari J., Oguri T., Kobayashi K., Satou K., Matsumiya H., Saito A., Terai T., Tanno Y., Nishioka K., Arakawa M., Wada K., Okada M., Ozaki K., Aoki N., Kitamura N., Sekine O., Suzuki Y., Matsuda M., Tanimoto H., Nakata K., Nakamori Y., Kusano N., et al. Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994). Jpn. J. Antibiot. 49 (1996) 419-455
21. Ikemoto H., Watanabe K., Mori T., Igari J., Oguri T., Kobayashi K., Satou K., Matsumiya H., Saito A., Terai T., Tanno Y., Nishioka K., Arakawa M., Wada K., Okada M., Ozaki K., Aoki N., Kitamura N., Sekine O., Suzuki Y., Tanimoto H., Nakata K., Nakamori Y., Nakatani T., Kusano N., et al. Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992). Jpn. J. Antibiot. 49 (1996) 34-70
22. Ikemoto H., Watanabe K., Mori T., Igari J., Oguri T., Kawaguchi H., Shimizu Y., Matsumiya H., Saito A., Terai T., Inoue H., Nakadate T., Ito C., Yosida T., Tanno Y., Ohno I., Nishioka K., Arakawa M., Igarashi K., Wada K., Okada M., Ozaki K., Aoki N., Kitamura N., Touyama M., et al. Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995). Jpn. J. Antibiot. 50 (1997) 421-459
23. Ikemoto H., Watanabe K., Mori T., Igari J., Oguri T., Shimizu Y., Terai T., Inoue H., Nakadate T., Ito C., Yoshida T., Ohno I., Tanno Y., Arakawa M., Igarashi K., Okada M., Ozaki K., Aoki N., Kitamura N., Sekine O., Suzuki Y., Nakata K., Nakatani T., Inagawa H., and Kusano N. Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996). Jpn. J. Antibiot. 51 (1998) 437-474
24. Imada A., Kondo M., Okonogi K., Yukishige K., and Kuno M. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic. Antimicrob Agents Chemother 27 (1985) 821-827
25. James W. Research on Obesity (1976), Her Majesty's Stationery Office, London
26. Jones R.N., Barry A.L., Thornsberry C., Fuchs P.C., and Packer R.R. The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam. Am J Clin Pathol 86 (1986) 608-618
27. Koeppe P., Hoffler D., and Strobel K. Pharmacokinetics and dose recommendations of carumonam in renal failure. Arzneimittelforschung 37 (1987) 65-69
28. Kumamoto Y., Tsukamoto T., Watanabe K., Kobayashi Y., Hirose T., Matsukawa M., Uchida H., Takahashi S., Kunishima Y., Matsuda S., Sato S., Ogihara M., Ishibashi K., Shigeta S., Fujime M., Fujita K., Yoshida H., Imafuku Y., Igari J., Murai M., Oguri T., Yamaguchi K., Matsumoto T., Kashitani F., Furuhama T., Kumon H., Monden K., Ooe H., Nishikawa M., Kohno S., Miyazaki Y., Izumikawa K., Yamaguchi T., Mochida C., Oka T., Kitamura M., Takano Y., and Matsuoka Y. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution. Jpn. J. Antibiot. 54 (2001) 185-216
29. Kumamoto Y., Tsukamoto T., Watanabe K., Kobayashi Y., Matsukawa M., Uchida H., Kunishima Y., Hirose T., Matsuda S., Sato S., Shigeta S., Fujime M., Fujita K., Yamaguti O., Ogihara M., Ishibashi K., Igari J., Takahashi K., Oguri T., Yoshida H., Imafuku Y., Yamaguchi K., Furuya N., Kashitani F., Murai M., Ooe H., Nishikawa M., Kumon H., Monden K., Oka T., Kitamura M., Kohno S., Tomono K., Miyazaki Y., Matsuoka Y., Fukuhara Y., Hirakata Y., and Aoki S. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2001). I. Susceptibility distribution. Jpn. J. Antibiot. 56 (2003) 396-423
30. Kumamoto Y., Tsukamoto T., Matsukawa M., Kunishima Y., Hirose T., Yamaguti O., Ishibashi K., Shigeta S., Suzutani T., Yoshida H., Imafuku Y., Murai M., Watanabe K., Kobayashi Y., Uchida H., Matsuda S., Sato S., Fujime M., Fujita K., Igari J., Oguri T., Yamaguchi K., Furuya N., Deguchi T., Ishihara S., Ooe H., Nishikawa M., Oka T., Kitamura M., Fukuhara Y., Kamidono S., Arakawa S., Kumon H., Monden K., Matsumoto T., Takahashi K., Naito S., Egashira T., Kohno S., Miyazaki Y., Hirakata Y., and Aoki S. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). I. Susceptibility distribution. Jpn. J. Antibiot. 57 (2004) 246-274
31. Kumamoto Y., Tsukamoto T., Matsukawa M., Kunishima Y., Hirose T., Shigeta S., Yamaguti O., Ishibashi K., Suzutani T., Yoshida H., Imafuku Y., Murai M., Watanabe K., Kobayashi Y., Uchida H., Matsuda S., Sato S., Fujime M., Fujita K., Igari J., Oguri T., Yamaguchi K., Furuya N., Deguchi T., Ishihara S., Ooe H., Oka T., Kitamura M., Fukuhara Y., Kamidono S., Arakawa S., Kumon H., Monden K., Matsumoto T., Muratani T., Naito S., Egashira T., Konishi T., Kohno S., Hirakata Y., Kondo A., Matsuda J., and Nakano M. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution. Jpn. J. Antibiot. 59 (2006) 177-200
32. McNulty C.A., Garden G.M., Ashby J., and Wise R. Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam. Antimicrob. Agents Chemother. 28 (1985) 425-427
33. Miller M.E., and Kornhauser D.M. Bromide pharmacokinetics in cystic fibrosis. Arch. Pediatr. Adolesc. Med. 148 (1994) 266-271
34. Morgan D.J., and Bray K.M. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin. Pharmacokinet. 26 (1994) 292-307
35. Mosteller R.D. Simplified calculation of body-surface area. N. Engl. J. Med. 317 (1987) 1098
36. Paap C.M., and Nahata M.C. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin. Pharmacokinet. 19 (1990) 280-318
37. Parke J., Holford N.H., and Charles B.G. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59 (1999) 19-29
38. Prandota J. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr. Infect. Dis. J. 6 (1987) 1111-1126
39. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 35 (1988) 542-578
40. Raimondi A., Mattina R., and Cocuzza C.E. Carumonam's in-vitro activity against gram-negative bacteria and its stability to their beta-lactamases. Chemioterapia 7 (1988) 3-9
41. Rey E., Treluyer J.M., and Pons G. Drug disposition in cystic fibrosis. Clin. Pharmacokinet. 35 (1998) 313-329
42. Ribbing J., and Jonsson E.N. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J. Pharmacokinet. Pharmacodyn. 31 (2004) 109-134
43. Rochat T., Slosman D.O., Pichard C., and Belli D.C. Body composition analysis by dual-energy x-ray absorptiometry in adults with cystic fibrosis. Chest 106 (1994) 800-805
44. Shinagawa N., Yura J., Manabe T., Mashita K., Ishikawa S., Mizuno A., Hirata K., Denno R., Mukaiya M., Ishibiki K., Ushijima Y., Aikawa N., Takuma K., Iwai S., Kunimatsu M., Ohtsuka K., Kinoshita H., Morimoto K., Fujimoto M., Tanimura H., Ohnishi H., Umemoto Y., Sakaguchi S., Dounishi H., Oda S., et al. Isolation rate of Pseudomonas aeruginosa from surgical infections and their susceptibilities. Jpn. J. Antibiot. 49 (1996) 544-554
45. Slosman D.O., Casez J.P., Pichard C., Rochat T., Fery F., Rizzoli R., Bonjour J.P., Morabia A., and Donath A. Assessment of whole-body composition with dual-energy x-ray absorptiometry. Radiology 185 (1992) 593-598
46. Sorgel F., Stephan U., Wiesemann H.G., Gottschalk B., Stehr C., Rey M., Bowing H.B., Dominick H.C., and Geldmacher von Mallinckrodt M. High dose treatment with antibiotics in cystic fibrosis-a reappraisal with special reference to the pharmacokinetics of β-lactams and new fluoroquinolones in adult CF-patients. Infection 15 (1987) 385-396
47. Sweetman S.C. Martindale: the complete drug reference [online] (2009), Pharmaceutical Press, London 36. http://www.medicinescomplete.com/
48. Touw D.J. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm. World Sci. 20 (1998) 149-160
49. Touw D.J., Vinks A.A., Heijerman H.G., Hermans J., and Bakker W. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther. Drug. Monit. 16 (1994) 125-131
50. Touw D.J., Vinks A.A., Heijerman H.G., and Bakker W. Prospective evaluation of a dose prediction algorithm for intravenous tobramycin in adolescent and adult patients with cystic fibrosis. Ther. Drug Monit. 18 (1996) 118-123
51. Touw D.J., Vinks A.A., Mouton J.W., and Horrevorts A.M. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin. Pharmacokinet. 35 (1998) 437-459
52. Vinks A.A., van Rossem R.N., Mathot R.A., Heijerman H.G., and Mouton J.W. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob. Agents Chemother. 51 (2007) 3049-3055
53. Wang J.P., Unadkat J.D., al-Habet S.M., O'Sullivan T.A., Williams-Warren J., Smith A.L., and Ramsey B. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. Clin. Pharmacol. Ther. 54 (1993) 293-302
54. West G.B., Brown J.H., and Enquist B.J. A general model for the origin of allometric scaling laws in biology. Science 276 (1997) 122-126
55. West G.B., Brown J.H., and Enquist B.J. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284 (1999) 1677-1679
56. Yoshida K., Mitani M., Naeshiro I., Torii H., and Tanayama S. Disposition of carumonam (AMA-1080/Ro 17-2301), a new N-sulfonated monocyclic β-lactam, in rats and dogs. Antimicrob. Agents Chemother. 29 (1986) 1017-1024
57. Zhao W.H., Hu Z.Q., and Shimura T. Potency of IMP-10 metallo-beta-lactamase in hydrolysing various antipseudomonal beta-lactams. J Med Microbiol 57 (2008) 974-979